The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer
2002

Inflammation and Survival in Lung Cancer Patients

Sample size: 106 publication 10 minutes Evidence: moderate

Author Information

Author(s): Scott H R, McMillan D C, Forrest L M, Brown D J F, McArdle C S, Milroy R

Primary Institution: Wishaw General Hospital, University Department of Surgery, Royal Infirmary, Stobhill Hospital

Hypothesis

The study aims to examine the relationship between the magnitude of the systemic inflammatory response and weight loss, performance status, and survival in patients with inoperable non-small cell lung cancer.

Conclusion

The study found that a greater magnitude of systemic inflammatory response is associated with increased weight loss, poorer performance status, more fatigue, and reduced survival in patients with inoperable non-small cell lung cancer.

Supporting Evidence

  • The majority of patients had elevated C-reactive protein concentrations, indicating a systemic inflammatory response.
  • An increase in systemic inflammatory response was linked to greater weight loss and poorer performance status.
  • Median survival was significantly lower for patients with higher C-reactive protein levels.

Takeaway

Patients with lung cancer who have more inflammation in their body tend to lose more weight and feel worse, which can lead to shorter survival times.

Methodology

The study included patients with inoperable NSCLC, measuring weight loss, performance status, and blood parameters, and performed survival analysis using the Cox proportional hazard model.

Potential Biases

Potential biases may arise from the observational nature of the study and reliance on clinical assessments.

Limitations

The study may not account for all variables affecting survival and relies on patient self-reporting for quality of life measures.

Participant Demographics

The majority of participants were male, over the age of 60, with advanced stage III and IV lung cancer.

Statistical Information

P-Value

P<0.001

Confidence Interval

95% CI 1.414–2.650

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600466

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication